Aplastic anemia (AA) is a rare but life-threatening bone marrow failure syndrome, which is diagnosed based on cytopenias in peripheral blood and hypocellularity in bone marrow. The distinction between AA and hypocellular myelodysplastic syndrome (MDS) is often difficult, and AA evolves into MDS or AML at a 10-year cumulative incidence of 3.1% to 9.6%. 1, 2 As AA patients often respond to immunosuppressive therapy, an immune pathophysiology is widely assumed. 3 The evolution of clonal cytogenetic aberrations in hematopoietic cells and the association with clonal paroxysmal nocturnal hemoglobinuria (PNH) suggest that some patients have a clonal hematopoietic disease. 4 Data by Walter and colleagues show that 74%
of MDS patients harbour a mutation in at least one of 94 candidate genes, while mutations can still be found in 68% of MDS patients when a core set of 25 genes is analyzed. 5 We hypothesized that mutations that are found in MDS patients may also be present in patients with AA and therefore evaluated the mutation profile of 42 genes in AA patients.
Thirty eight patients with aplastic anemia who were diagnosed and treated in our institution were included in our study. Patient characteristics are described in detail in Supplementary Methods and Supplementary Table S1 . Written informed consent was obtained according to the Declaration of Helsinki, and the studies were approved by the institutional review board. Coding exons of the 33 most frequently mutated genes in myeloid malignancies (Table S2) were sequenced on the SOLiD TM system (Life Technologies, Darmstadt, Germany) as described in Supplementary Data. Nine other genes mutated in myeloid malignancies including TERT, all candidate mutations from next generation sequencing, exon 13 of ASXL1, and exons 3 to 11 of TET2 were sequenced by Sanger sequencing or analyzed by fragment analysis (Table S2) . Confirmed mutations were also evaluated in germline DNA (CD3+ T cells from peripheral blood or hair follicles).
Eleven of 38 patients had moderate, 12 severe, and 15 very severe AA. Median age of AA patients at diagnosis was 30 years (range 9-79). Three patients (8%) had abnormal cytogenetics (Table S1 ). In 17 patients (44.7%), a GPI-deficient clone suggesting PNH/AA overlap syndrome was present. Twenty-two patients underwent allogeneic or syngeneic transplantation. The median follow-up duration from diagnosis of patients alive was 7 years. 35 of 38 patients were alive at last follow-up.
Supporting the diagnosis of AA, telomeres in peripheral blood leukocytes were significantly shorter in AA patients (n=13) than in age matched healthy controls (n=20) (median age AA, 44 years, median age healthy controls, 43 years, P=.43; mean T/S ratio AA patients 1.43, mean T/S ratio healthy controls, 2.48, P<.001, Supplementary Figure S1 ). Next generation sequencing yielded an average coverage of 2015 reads per amplicon. In total 3 somatic mutations were identified in 2 patients in the examined MDS candidate genes (5.3%, Table 1 and Supplementary Figure S2 ). One patient had a somatic missense mutation in SLIT1, and one patient with severe AA had two somatic mutations, one missense mutation in SETPB1
(D868N) and one frameshift mutation in ASXL1 (G645fs). This patient was diagnosed with severe AA at age 14 and received 4 courses of immunosuppressive therapy.
After the first cycle of ATG the patient was in remission for 4 years. mutations have been identified previously at low allelic ratios of 8 and 9 percent in two aplastic anemia patients. 9 We excluded mutations from further validation with allelic burden below 15% as these mutations cannot be validated by Sanger sequencing and their pathogenic role is unclear. SETBP1 mutations are recurrent in MDS at a low frequency, 10 and are associated with atypical CML and ASXL1 mutations as in our patient. 11 MYBL2 is a candidate tumor suppressor gene that is located in the commonly deleted region of MDS patients with del20q, 12 and haploinsufficiency of this gene predisposes to MDS in a mouse model. 13 
SLIT1
mutations have been first reported in AA patients by Saito et al. 14 The SLIT/ROBO pathway regulates axon guidance and has been implicated as a tumor suppressor.
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Considering the 25 genes that were recently analyzed by Walter et al. 5 in MDS patients and were also included in our analysis, somatic mutations were found in 68% of MDS patients but only 5.3% of AA patients (2 patients, one had likely progressed to MDS). Patient characteristics of the Walter study and our study are listed in Supplementary Table S3 . We therefore suggest that mutation analysis of myelodysplasia-related genes may help to distinguish AA from MDS in ambiguous cases and may identify patients who are at risk for MDS-progression. Whether sequential mutation analysis provides prognostic information and is superior to cytogenetic analysis will be analyzed prospectively in the future. Recently, germline mutations in thrombopoietin have been identified in familial aplastic anemia. 16 In addition, two patients with AA have been described who had mutations in MPL, the receptor of thrombopoietin. 17 However, we have not identified MPL mutations in our patient cohort.
In summary, we identified somatic mutations in 5.3 percent of AA patients, of whom one had progressed to MDS. Our analysis suggests that mutations in myeloid malignancy-related genes are rare in AA patients. 
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Supplementary methods
Thirty eight patients with aplastic anemia who were diagnosed and treated in our institution were included in this study. Fanconi anemia was excluded in only one patient experimentally. However, none of the patients presented with clinical, nonhematologic abnormalities indicating Fanconi anemia (eg. short stature, abnormalities of the skin, bone, eyes, kidneys or ears). Twenty two patients underwent allogeneic hematopoietic stem cell transplantation for whom DNA from peripheral blood mononuclear cells was available within 4 weeks before transplantation. We expanded our cohort with patients not undergoing transplantation (n=16) for whom bone marrow (n=5) or peripheral blood (n=11) samples were available at a time when the patients were cytopenic in at least one blood lineage (time from diagnosis to sample harvest 2 years, range 0 -21 years). We used DNA from eyebrow hair follicles or sorted CD3+ cells from peripheral blood as germline control. Peripheral blood leukocytes from 20 healthy volunteers were used for telomere length assessment.
For flow cytometric diagnosis of a PNH cell population, at least two cell lineages with significant GPI-deficient populations were required. The following antibodies were used to identify GPI-deficient cells: CD55 and CD59 on erythrocytes, FLAER on CD24 positive granulocytes and FLAER on CD14 positive monocytes. PNH was defined as presence of marker-negative populations exceeding the cut-off value of 1% in at least two lineages. Cytogenetic analysis was performed by G-and Rbanding at diagnosis, and chromosomal abnormalities were described according to the International System for Human Cytogenetic Nomenclature. The presence of a PNH clone was evaluated in the neutrophil, monocytic and erythroid lineages by flow cytometric analysis at diagnosis and during the course of the disease.
Mononuclear cells from BM and/or blood specimens were enriched by Ficoll density gradient centrifugation and were stored at -70°C in liquid nitrogen until use. Genomic DNA was extracted from samples using the All Prep DNA/RNA Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations, and was whole genome amplified (GenomePlex whole genome amplification kit, Sigma-Aldrich, Seelze, Germany). The coding exons of 33 MDS-related genes (Table S2) Individual reads were 75 basepairs long.
Sequence reads were assigned to their patient-specific barcode, and sequences were analyzed twice separately using the DNAnexus software (DNAnexus.com) and an in-house pipeline of bioinformatics software. The color-space reads were aligned with NovoAlignCS and genotyped with GATK's Unified Genotyper.
SNV discovery
was performed across all samples using standard parameters and a maximum coverage of 10,000. The resulting list of candidate single nucleotide variants (SNV) was filtered with R. First, mutations outside the coding region were excluded. Second, known single nucleotide polymorphisms (dbSNP version 137) were removed. Third, variants with a quality score of less than 8000 or a frequency of less than 15% were excluded. The 15% cutoff was chosen as we wanted to consider only variants that can be validated by Sanger sequencing. To determine the coverage of genomic intervals, the data was processed with BEDTools 2 and analysed in R. All candidate SNVs were validated by Sanger sequencing and only those confirmed either in genomic DNA or in an independently whole genome-amplified DNA sample are reported. Exon 13 of ASXL1 and exons 3 to 11 of TET2 were also sequenced by
Sanger sequencing in addition to 9 other genes (Table S2) , which were only sequenced by Sanger sequencing or fragment analysis using a 3130 Genetic Analyzer (Applied Biosystems, Darmstadt, Germany). Confirmed mutations were also sequenced in germline DNA.
Telomere length was evaluated by monochrome multiplex quantitative polymerase chain reaction (PCR) using primers for telomeres and the reference gene beta-globin (Table S4 ) as described before 3 in the same samples that were used for molecular analysis (if sufficient material was available). DNA was assayed in duplicate in two independent runs on a MyIQ2 two-color real-time PCR detection system (Bio-Rad Laboratories, München, Germany). Amplification efficiency was 90 to 100%. T/S ratio was calculated by dividing the copy number of the telomere template T by the copy number of the beta-globin template S. The average T/S ratio was calculated from two independent runs.
Pair-wise comparisons of variables were performed for exploratory purposes using Figure S1 : Telomere length in peripheral blood leukocytes of healthy volunteers (n=20) and aplastic anemia patients (n=13). 
